Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 9/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9545095 | 1.00 | LMNA (0.42) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL1147732 | 1.00 | LMNA (0.42) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL27358898 | 1.00 | LMNA (0.42) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL27645826 | 1.00 | LMNA (0.42) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL8682114 | 1.00 | LMNA (0.42) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL3394794 | 1.00 | LMNA (0.42) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL9137980 | 1.00 | LMNA (0.42) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL1147850 | 1.00 | LMNA (0.42) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL1147869 | 1.00 | LMNA (0.42) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL15016341 | 1.00 | LMNA (0.42) | LMNACYP2D6SPHK1GMNNPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325525-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2024-10-03 | — | — | US | claimed |
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2023-11-30 | — | — | US | claimed |
| US-20260077038-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069684-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20240325525-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-12064479-B2 | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof | AKAGERA MEDICINES, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20080207544-A1 | Compositions And Methods For Delivery Of Agents Into Cells | SULLIVAN SEAN M | 2008-08-28 | — | — | US | disclosed |
| WO-2006081396-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS INTO CELLS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-0799059-B1 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORP (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6383814-B1 | AEROSOLIZED SOLUTION INCLUDES BIOLOGICALLY ACTIVE MOLECULE, CATIONIC AMPHIPHILE FOR TRANSPORT OF ACTIVE MOLECULE INTO CELL, AND POLYETHYLENE GLYCOL-PHOSPHATIDYLETHANOLAMINE; GENE THERAPY; ANTISENSE AGENTS | GENZYME CORPORATION | 2002-05-07 | — | — | US | disclosed |
| EP-0845981-A1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5747471-A | DNA, RNA AND ANTISENSE POLYNUCLEOTIDES FOR GENE THERAPY | GENZYME CORPORATION (US) | 1998-05-05 | — | — | US | disclosed |
| WO-1998013026-A1 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-04-02 | — | — | WO | disclosed |
| US-5719131-A | GENE THERAPY | GENZYME CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1998002191-A2 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1998002190-A2 | CATIONIC AMPHIPHILE/DNA COMPLEXES | GENZYME CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1997046223-A1 | COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0799059-A1 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996018372-A2 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069684-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | PHOSPHO1, PLTP, SGMS1 | LMNA 39/4885CYP2D6 3460/4885SPHK1 59/4885 |
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | PHOSPHO1, PTDSS1, PTDSS2 | LMNA 136/4885CYP2D6 4430/4885SPHK1 39/4885 |
| US-20260077038-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | PHOSPHO1, LNPK, SGMS2 | LMNA 153/4885CYP2D6 4346/4885SPHK1 67/4885 |
| US-12064479-B2 | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof | PHOSPHO1, PTDSS1, PTDSS2 | LMNA 136/4885CYP2D6 4430/4885SPHK1 39/4885 |
| US-20080207544-A1 | Compositions And Methods For Delivery Of Agents Into Cells | ANXA6, ANXA5, SGMS1 | LMNA 626/4885CYP2D6 4677/4885SPHK1 554/4885 |
| US-20240325525-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | PHOSPHO1, PTDSS1, PTDSS2 | LMNA 136/4885CYP2D6 4430/4885SPHK1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.